MetaCap

Lipocine (LPCN) vs Psyence Biomedical (PBM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lipocine (LPCN) has outperformed Psyence Biomedical (PBM) over the past year, losing 53.2% versus a loss of 94.9%. Lipocine is the larger company by market cap ($16.4 million vs $15.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LPCN-53.16%PBM-94.90%
+274%+80%-114%
Nov 21, 20251 yearNov 20, 2026
LPCN-92.23%PBM-100.00%
+73%-17%-108%
Dec 6, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LPCN versus PBM key metrics
MetricLPCNPBM
Share price$1.48$2.97
Market cap$16.39M$15.80M
1-day change-1.33%+3.85%
YTD return-81.57%-89.90%
1-year return-53.16%-94.90%
5-year return-92.30%—
EPS (TTM)$-1.32$-12.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.98M—
Revenue growth (YoY)-82.35%—
Net income (latest FY)$-9.63M$1.01M
Operating margin-524.69%—
Net margin-487.06%—
52-week high$12.37$73.44
52-week low$1.36$1.92
Distance from 52-week high-88.04%-95.96%
Analyst consensusnone—
Avg. price target upside+237.84%—
Average volume1.84M61.93K
Shares outstanding11.07M5.32M
Employees1412
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LPCN has outperformed PBM by 41.7 percentage points over the past year.

About Lipocine

LPCN stock →

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Psyence Biomedical

PBM stock →

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

LPCN vs PBM FAQ

Which is bigger, Lipocine or Psyence Biomedical?

Lipocine (LPCN) is larger, with a market capitalization of $16.39M compared with $15.80M for Psyence Biomedical (PBM).

Which stock has performed better over the past year, LPCN or PBM?

LPCN returned -53.16% over the past 12 months, compared with -94.90% for PBM (price return, excluding dividends). Past performance does not predict future results.

Are Lipocine and Psyence Biomedical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons